89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of cardiology

San francisco, feb. 21, 2023 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data from the phase 2 entrigue study in severe hypertriglyceridemia (shtg) will be presented at the american college of cardiology's 72nd annual scientific session together with world congress of cardiology to be held march 4-6, 2023 in new orleans.
ETNB Ratings Summary
ETNB Quant Ranking